SNDX SYNDAX PHARMACEUTICALS

Syndax Announces Participation in March Investor Conferences

Syndax Announces Participation in March Investor Conferences

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

  • TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside chat on Tuesday, March 4, 2025, at 3:10 p.m. ET
  • Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 13, 2025, at 8:30 a.m. ET

A live webcast of the fireside chats will be available in the Investor section of the Company's website at , where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on and .

Syndax Contacts

Sharon Klahre

Syndax Pharmaceuticals, Inc.



Tel 781.684.9827

SNDX-G



EN
25/02/2025

Underlying

SNDXSYNDAX PHARMACEUTICALS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SYNDAX PHARMACEUTICALS

 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: ), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted inducement awards to purchase up to 282,000 shares of common stock to 12 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement...

March 5, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and...

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, ...

March 3, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Announces Participation in March Investor Conferences

Syndax Announces Participation in March Investor Conferences WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside chat on Tuesday, March 4, 2025, at 3:10 p.m. ETBarclays 27th Annual Global H...

February 25, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results...

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025 WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on...

February 24, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 46.14
BA BOEING COMPANY ...
DXCM DEXCOM INC. ... (+55)

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

BA BOEING COMPANY (THE)
DXCM DEXCOM INC.
PPG PPG INDUSTRIES INC.
CNHI CNH INDUSTRIAL NV
UCTT ULTRA CLEAN HOLDINGS INC.
QYM SOCIEDAD QUIMICA Y MINERA DE CHILE S.A. SERIES B ADS
SLAB SILICON LABORATORIES INC.
SEE SEALED AIR CORPORATION
SEDG SOLAREDGE TECHNOLOGIES INC.
SCL STEPAN COMPANY
RVNC REVANCE THERAPEUTICS INC.
PODD INSULET CORPORATION
MKSI MKS INSTRUMENTS INC.
MIDD MIDDLEBY CORPORATION
LGIH LGI HOMES INC.
HUN HUNTSMAN CORPORATION
HII HUNTINGTON INGALLS INDUSTRIES INC.
FELE FRANKLIN ELECTRIC CO. INC.
DIOD DIODES INCORPORATED
DGII DIGI INTERNATIONAL INC.
CSIQ CANADIAN SOLAR INC.
COO COOPER COMPANIES INC.
CMP COMPASS MINERALS INTERNATIONAL INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
B BARNES GROUP INC.
AMBA AMBARELLA INC.
ALNY ALNYLAM PHARMACEUTICALS INC
ALB ALBEMARLE CORPORATION
MHK MOHAWK INDUSTRIES INC.
ERII ENERGY RECOVERY INC.
HPQ HP INC.
CG. CENTERRA GOLD INC.
FR. FIRST MAJESTIC SILVER CORP.
DOOR MASONITE INTERNATIONAL CORP.
LEG LEG IMMOBILIEN AG
ELY CALLAWAY GOLF COMPANY
FMC FMC CORPORATION
JKS JINKOSOLAR HOLDING CO. LTD. SPONSORED ADR
KMT KENNAMETAL INC.
TTC TORO COMPANY
XYL XYLEM INC.
AOS A. O. SMITH CORPORATION
ASIX ADVANSIX INC.
NOVT NOVANTA INC
SNDX SYNDAX PHARMACEUTICALS
IRTC IRHYTHM TECHNOLOGIES INC.
ASML ASML HOLDING N.V.
LTHM LIVENT
HROW HARROW HEALTH INC.
KROS KEROS THERAPEUTICS
MP MP MATERIALS CORP (A)
ALGM ALLEGRO MICROSYSTEMS
OI O-I GLASS INC
WOLF WOLFSPEED INC
TGI TGI INFRASTRUCTURES LTD
09/22/23 September 22, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch